2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4476 Clinical outcomes with abbreviated course of R-mini-CHOP for very elderly patients with limited stage diffuse large B cell lymphoma (LS-DLBCL)

Justine P Enns, MD, Josie Ford2, Jacob D. Soumerai, MD3, Jeremy S. Abramson, MD4, Julie Haydu, MD, PhD5, Patrick Connor Johnson, MD6
1 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
2 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
3 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
4 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
5 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
6 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States

Introduction: Diffuse large B cell lymphoma (DLBCL) is an aggressive but potentially curable lymphoma which predominantly affects older adults, with a third of patients diagnosed over age 75. R-miniCHOP administered for 6-cycles has demonstrated efficacy in patients ≥ 80 years with DLBCL. However, trials using R-miniCHOP primarily focused on patients with advanced-stage disease. To our knowledge, there is no data on how to manage limited stage (LS) DLBCL in frail older adults who are not candidates for full-dose R-CHOP. This retrospective study evaluated a cohort of very elderly patients diagnosed with LS-DLBCL who were treated with an abbreviated course of R-miniCHOP with or without radiotherapy.

Methods: We conducted a retrospective analysis of adult patients aged 80 years and older diagnosed with LS (Ann Arbor stages 1 and 2) DLBCL who received 3 or 4 cycles of R-miniCHOP with or without radiotherapy at the Massachusetts General Hospital (MGH) Cancer Center or MGH-affiliated community practices between January 2015 and March 2025. We manually extracted clinical information from the electronic health record (EHR) via comprehensive chart review and used descriptive statistics to summarize patients’ sociodemographic and clinical characteristics, adverse events, and survival at important time points (6 months, 1 year, 2 years). We used the Kaplan Meier method to determine overall survival (OS) and event-free survival (EFS), with an event considered death, progression, or the start of a new therapy.

Results: We identified 21 patients with pathology-confirmed diagnosis of LS-DLBCL who were over the age of 80 at the time of diagnosis and were intended to receive treatment with 3 or 4 cycles of R-miniCHOP. The majority of the patients were male (57%), white (86%), had non-Germinal Center B-cell-like cell of origin (62%), and were classified as Ann Arbor Stage I disease (86%). Eastern Cooperative Oncology Group performance status was 0-1 in 16 patients (76%) and 2-3 in 5 patients (24%). Most patients completed 3 cycles (14 patients, 67%) or 4 cycles (4 patients, 19%) of chemoimmunotherapy, while 3 patients (15%) received only 1-2 cycles of therapy before discontinuing treatment. Reasons for discontinuing therapy prematurely were for severe infection (N=1) and treatment-related cardiomyopathy (N=2).  76% (16 patients) received consolidative radiotherapy. Median follow up time was 4.2 years. The overall response rate was 91%, with 18 (86%) patients achieving a complete response and 1 (5%) achieving a partial response. One patient progressed during treatment. The OS and EFS rates at 6 months, 1-year, and 2-years were all 86% (95% confidence interval [CI] 62-95). The Median OS and EFS were 5.6 years (95% confidence interval 3.6-not reached). Causes of death included progressive disease (N=1), treatment-related toxicity (N=2), and other causes (N=6). Deaths from other causes occurred at a median of 4.6 years after treatment initiation (range 2.3-7.1). Within 6 months of initiating therapy, 2 patients (10%) had emergency department visits without admissions, and 8 patients (60%) required hospital admission, with 1 (5%) requiring an intensive care unit admission.

Conclusion: Though limited by a small sample size, to our knowledge this data is the first to demonstrate outcomes with an abbreviated course of R-mini-CHOP in limited stage DLBCL. These findings suggest that elderly patients with limited-stage DLBCL receiving abbreviated courses (3-4 cycles) of R-miniCHOP and radiotherapy can achieve excellent survival outcomes. Notably a subset of patients experienced treatment-related mortality; additional work is needed to understand which patients will do poorly with chemoimmunotherapy in this patient population.

Justine P Enns, MD: No relevant conflicts of interest to declare.